verapamil has been researched along with linezolid in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Creemer, CN; Dai, M; Davis, DC; Kyei-Baffour, K; Mohammad, H; Seleem, MN; Younis, W | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdelghany, TM; Bayoumi, SA; Disouky, AM; El-Morsy, A; Elshafeey, A; Mancy, AS; Mayhoub, AS; Mohammad, H; Seleem, MA; Seleem, MN | 1 |
| Abdelghany, TM; Fayed, E; Mayhoub, AS; Mohammad, H; Seleem, MN; Yahia, E | 1 |
| Abd Rabo Moustafa, MM; Abdelghany, TM; Eissa, IH; Elshafeey, A; Mayhoub, AS; Mohammad, H; Qassem, OA; Seleem, MN; Younis, W | 1 |
| Abdelghany, TM; Elkabbany, AH; Ghiaty, A; Hagras, M; Hegazy, YA; Mayhoub, AS; Mohammad, H; Seleem, MN | 1 |
| Eslamimehr, S; Franzblau, SG; Kong, Y; Kurosu, M; Lemieux, MR; Mitachi, K; Park, F; Pressly, JD; Siricilla, S; Wang, Y; Yang, D | 1 |
| Abutaleb, NS; Elsebaei, MM; Gowher, H; Mayhoub, AS; Michie, AR; Mohammad, H; Moustafa, MM; Norvil, AB; Samir, A; Samy, H; Seleem, MN | 1 |
| Abutaleb, NS; Alhashimi, M; Kassab, AE; Mayhoub, AS; Mohamed, KO; Seleem, MN; Shahin, IG; Taher, AT | 1 |
| Bora, A; Deka, B; Devi, MV; Dihingia, A; Pahari, P; Sarma, S; Sen, T; Singh, AK; Suri, M | 1 |
| Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S | 1 |
1 review(s) available for verapamil and linezolid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 other study(ies) available for verapamil and linezolid
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Caco-2 Cells; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Humans; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Molecular Structure; Nitriles; Staphylococcus aureus; Structure-Activity Relationship; Vancomycin Resistance | 2015 |
Second-Generation Phenylthiazole Antibiotics with Enhanced Pharmacokinetic Properties.
Topics: Anti-Bacterial Agents; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Hydrazines; Keratinocytes; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Thiazoles | 2016 |
Phenylthiazole antibiotics: A metabolism-guided approach to overcome short duration of action.
Topics: Anti-Bacterial Agents; Cells, Cultured; Drug Resistance, Bacterial; Drug Stability; Half-Life; Humans; Keratinocytes; Methicillin-Resistant Staphylococcus aureus; Structure-Activity Relationship; Thiazoles | 2017 |
Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Carbanilides; Drug Resistance, Bacterial; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; Staphylococcus aureus; Vancomycin Resistance | 2017 |
Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Biological Availability; Cell Line; Chemical Phenomena; Cricetinae; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxadiazoles; Rats; Solubility; Structure-Activity Relationship; Thiazoles | 2018 |
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
Topics: Administration, Oral; Animals; Antitubercular Agents; Area Under Curve; Biological Availability; Caco-2 Cells; Diterpenes; Female; Half-Life; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pleuromutilins; Polycyclic Compounds | 2018 |
Lipophilic efficient phenylthiazoles with potent undecaprenyl pyrophosphatase inhibitory activity.
Topics: Animals; Anti-Bacterial Agents; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line; Chromatography, Liquid; Enzyme Inhibitors; Lipids; Macrophages; Mass Spectrometry; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Proton Magnetic Resonance Spectroscopy; Pyrophosphatases; Structure-Activity Relationship; Thiazoles | 2019 |
Evaluation of N-phenyl-2-aminothiazoles for treatment of multi-drug resistant and intracellular Staphylococcus aureus infections.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Staphylococcal Infections; Structure-Activity Relationship; Thiazoles | 2020 |
Potentiating the intracellular killing of Staphylococcus aureus by dihydroquinazoline analogues as NorA efflux pump inhibitor.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cell Survival; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Multidrug Resistance-Associated Proteins; Quinazolines; Staphylococcus aureus; Structure-Activity Relationship; THP-1 Cells | 2022 |
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil | 2023 |